Roche's ENSPRYNG Cuts Relapse Risk In Rare Neurological Disease

Roche said Phase III METEOROID results showed ENSPRYNG reduced relapse risk by 68% versus placebo in patients with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). The readout supports the drug's clinical profile and is a favorable development for Roche's neuroscience/rare-disease franchise. The update is positive for the stock but likely limited in immediate market impact given the narrow indication.

Analysis

Roche said Phase III METEOROID results showed ENSPRYNG reduced relapse risk by 68% versus placebo in patients with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). The readout supports the drug's clinical profile and is a favorable development for Roche's neuroscience/rare-disease franchise. The update is positive for the stock but likely limited in immediate market impact given the narrow indication.